Immuneering Q3: 86% 9-month OS in pancreatic cancer; raised $225M; cash into 2029

Immuneering Corp

2025-Q3 EPS reported -$1.20

Reported 86% overall survival at 9 months in first-line pancreatic cancer with atebimetinib + mGnP.
Raised $225M in financing ($175M public offering + $25M Sanofi placement + $25M private placement).
Cash and equivalents $227.6M as of Sep 30, 2025; cash runway extended into 2029.
Granted US composition of matter patent for atebimetinib expiring 2042, with potential term extension.
New case studies show complete response and conversion to curative-intent surgery with atebimetinib + FOLFIRINOX.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.